Search research articles
Contact Us
Filters
Showing results (101-110 of 106) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 106 results.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The New England Journal of Medicine
|
March 16, 2010
Effects of intensive blood-pressure control in type 2 diabetes mellitus
, William C Cushman, Gregory W Evans, et al.
JACC. Advances
|
February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design
Jorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Archives of Internal Medicine
|
January 30, 2008
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Jackson T Wright, Sonja Harris-Haywood, Sara Pressel, et al.
Hypertension (Dallas, Tex. : 1979)
|
July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
Frans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
William C Cushman, Barry R Davis, Sara L Pressel, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 106) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 106 results.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
December 19, 2008
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
William C Cushman, Charles E Ford, Paula T Einhorn, et al.
The New England Journal of Medicine
|
March 16, 2010
Effects of intensive blood-pressure control in type 2 diabetes mellitus
, William C Cushman, Gregory W Evans, et al.
JACC. Advances
|
February 17, 2026
Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design
Jorge Plutzky, Pam R Taub, Deepak L Bhatt, et al.
Archives of Internal Medicine
|
January 30, 2008
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Jackson T Wright, Sonja Harris-Haywood, Sara Pressel, et al.
Hypertension (Dallas, Tex. : 1979)
|
July 26, 2006
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
Frans H H Leenen, Chuke E Nwachuku, Henry R Black, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)
|
January 13, 2012
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
William C Cushman, Barry R Davis, Sara L Pressel, et al.
Page
of 11